targeting mage-c1ct7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines针对mage-c1ct7表达增加细胞敏感性的蛋白酶体抑制剂bortezomib多发性骨髓瘤细胞系.pdf

Targeting MAGE-C1/CT7 Expression Increases Cell Sensitivity to the Proteasome Inhibitor Bortezomib in Multiple Myeloma Cell Lines 1 2 2 3 2 Fabricio de Carvalho *, Erico T. Costa , Anamaria A. Camargo , Juliana C. Gregorio , Cibele Masotti , 1 4 5 6 Valeria C.C. Andrade , Bryan E. Strauss , Otavia L. Caballero , Djordje Atanackovic , Gisele W.B. Colleoni1 ˜ ˜ 1 Disciplina de Hematologia e Hemoterapia, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, 2 Laboratory of Molecular Biology and Genomics, Ludwig Institute for ˜ ˜ Cancer Research, Sao Paulo, Brazil, 3 Recepta Biopharma, Ludwig Institute for Cancer Research, Sao Paulo, Brazil, 4 Setor de Vetores Virais, Faculdade de Medicina, ´ ´ ˜ Laboratorio de Genetica e Cardiologia Molecular, InCor, Sao Paulo, Brazil, 5 Ludwig Collaborative Group, Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 6 Department of Medicine II, Oncology/Hematology/Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Abstract The MAGE-C1/CT7 encodes a cancer/testis antigen (CTA), is located on the chromosomal region Xq26–27 and is highly polymorphic in humans. MAGE-C1/CT7 is frequently expressed in multiple myeloma (MM) that may be a potential target for immunotherapy in this still incurable disease. MA